HLA-C and neoplasm: ISG+ DCs are found primarily within tumors, where tumor-derived IFN-β, a high-affinity member of the type I IFN family, induces ISG+ DCs to activate CD8+ T cells through “cross-dressing” of peptide-MHC (pMHC) complexes and their surface expression, enhancing cytotoxicity and promoting tumor regression [63].